Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
cystadenocarcinoma/glutathione
Krækjan er vistuð á klemmuspjaldið
10 niðurstöður
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer. The present study assessed
A role of glutathione in resistance mechanisms to cis-diamminedichloroplatinum(ii) in human ovarian-cancer cell-lines in-vitro.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The effects of D,L-buthionine-S, R-sulphoximine (BSO) on the cellular glutathione (GSH) levels and cis-diamminedichloroplatinum (II) (CDDP) sensitivity of human ovarian cancer cell lines (HRA, KK and MH) with different sensitivity to CDDP were examined. HRA cells were derived from ascites of a
Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
A cis-diamminedichloroplatinum (II) (CDDP)-resistant cell line (NOS2CR) demonstrated 7.4-fold greater resistance to CDDP compared with the parental cell line (NOS2) established from a patient with serous cystadenocarcinoma of the ovary. We investigated the role of enzyme systems associated with
Clear cell papillary cystadenocarcinoma of the epididymis: a case report and immunohistochemistry of markers for renal cell carcinoma.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Neoplasms of the epididymis are uncommon, and malignant tumors are extremely rare. We report a case of clear cell papillary cystadenocarcinoma of the epididymis presenting with a long history of painless scrotal mass on the left side. Immunohistochemical markers for clear cell renal cell carcinoma
Immunohistochemical analysis of glutathione S-transferase mu expression in ovarian tumors.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
To explore the association between Glutathione S-transferase (GST) -mu expression and clinicopathologic features in ovarian tumors.
METHODS
Immunohistochemical study was made to investigate GST-mu expression in diverse ovarian tumors.
RESULTS
All 75 ovarian tumors expressed GST-mu. There
Long-term prognostic factors for chemotherapy of ovarian cancer.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Patients with progressive ovarian cancer who underwent a remission-induction therapy in our department; intermittent chemotherapy (IC) of CDDP was performed every 3 months, and good outcome has been obtained. However, ineffective cases are sporadically seen. As long-term prognostic factors
A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
A newly synthesized calmodulin antagonist, (S)-P-(2-aminoethyloxy)-N-[2-(4-benzyloxy-carbonylpiperazinyl++ +)-1-(P-methoxybenzyl)ethyl]-N-methylbenzenesulfonamide dihydrochloride (W-77), acts as a calcium-independent uncompetitive antagonist which binds to glutathione-S-transferase (GST). We
Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
To investigate differences in resistance to cis-diamminedichloroplatinum(II) (CDDP) and diammine (1,1-cyclobutanecarboxylato)platinum(II) (CBDCA), and their newly developed derivative, ((-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum (II) (DWA2114R), four types of resistant
Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
It is known that some cancers show platinum complex resistance and that others show platinum complex sensitivity among ovarian cancers. Oxaliplatin (cis-[oxalato[trans-l-1, 2-diamino-cyclohexane] platinum[II]]; l-OHP), an active anti-cancer agent consisting of platinum, inhibits RNA synthesis and
Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The intracellular metabolism and cytotoxic effects of Ara-C and 2'-difluorodeoxycytidine (dFdC or Gemcitabine) administered with or without deoxycytidine (dCyd) were examined in cisplatin-resistant (2008/C13) and -sensitive (2008) human ovarian cystadenocarcinoma cells. Compared to 2008 cells,
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
